Rhabdomyosarcoma | A Drug Pipeline Analysis Report | Technavio
Sep. 04, 2018
LONDON--(BUSINESS WIRE)--Sep 4, 2018--Technavio has announced their latest pipeline analysis report on the drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat rhabdomyosarcoma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180904005796/en/
Technavio has published a new market research report on the global rhabdomyosarcoma market from 2018-2022. (Graphic: Business Wire)
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
Rhabdomyosarcoma: Market overview
Rhabdomyosarcoma is a rare soft-tissue cancer that affects the skeletal muscle tissue, bladder, or uterus. Despite being rare, it accounts for up to 40% of all the soft-tissue sarcomas. It is a highly malignant and aggressive form of cancer and is more common in people aged under 18 years. It is also referred to as a small-blue-round-cell tumor. Studies conducted on rhabdomyosarcoma have shown that there are no clear factors of risks associated with disease; however, it could result in congenital abnormalities. Rhabdomyosarcoma commonly affects the lungs, bone marrow, and bones. Certain genetic conditions, such as Li-Fraumeni syndrome, neurofibromatosis type 1, Beckwith-Wiedemann syndrome, pleuropulmonary blastoma, are likely to increase the chances of a person developing childhood rhabdomyosarcoma.
According to a senior market research analyst at Technavio, “The stem cells of rhabdomyosarcoma have been recently identified, and the researchers believe that fibroblast growth factor receptor 3 is the marker for the cells. Researchers are currently planning on conducting studies on the use of stem cell therapy for the treatment of rhabdomyosarcoma.”
Rhabdomyosarcoma: Segmentation analysis
This pipeline analysis report segments the rhabdomyosarcoma market based on therapies employed (monotherapy and combination therapy), RoA (oral, inhalation, and intravenous), therapeutic modality (small molecule, monoclonal antibody, biological, and peptide), targets (VEGF, tubulin, and others), MoA (VEGF inhibitor, tubulin polymerization inhibitor, and others), geographical segmentation (US, UK, Spain, Netherlands, Germany, Canada, and Belgium) and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapies employed, 70% of the molecules that are being investigated for the treatment of rhabdomyosarcoma are monotherapy. Monotherapy involves the use of a single drug to treat a particular disorder.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005796/en/
CONTACT: Infiniti Research
US: +1 844 778 0600
UK: +44 203 893 3400
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL OTHER HEALTH
SOURCE: Infiniti Research
Copyright Business Wire 2018.
PUB: 09/04/2018 03:07 PM/DISC: 09/04/2018 03:07 PM